Sarepta Therapeutics develops and sells gene therapy and other medicines for genetic diseases. It last closed at $14.77 on Nov 17, down 2.38% on the day. The average 12-month price target from 2 analysts is $19.00 (+28.6% from the last close), with a high of $20.00 and a low of $18.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in SRPT, 100% of them bullish and 0% bearish.
Only 2 firms rated SRPT in the past 90 days, not enough for a consensus
Average 12-month target
$19.00
▲ 28.6% upside
Based on 2 analysts who set a price target on SRPT in the past 90 days. The average target is $19.00, with a high of $20.00 and a low of $18.00, compared with the last close of $14.77.
Highest target$20.00
Average target$19.00
Lowest target$18.00
Latest rating changes
RBC CapitalTarget raised
Nov 6Hold$17 → $18
RBC CapitalMaintained
Oct 8Hold$17
JP MorganMaintained
Sep 30Hold$20
Piper SandlerMaintained
Jul 9Hold$20
Wolfe ResearchUpgrade
Jul 9Buy$27
Date
Firm
Action
Rating
Price target
Nov 6
RBC Capital
Target raised
Hold
$17 → $18
Oct 8
RBC Capital
Maintained
Hold
$17
Sep 30
JP Morgan
Maintained
Hold
$20
Jul 9
Piper Sandler
Maintained
Hold
$20
Jul 9
Wolfe Research
Upgrade
Buy
$27
Loading…
Technical Analysis
SRPT · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 19% below its 20 day and 24% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), oversold. The nearest support is the swing low (Aug 3) at $14.75, and the nearest resistance the Pivot at $14.82.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 6.2%/day
Key levels
$24.6852 week high+67.1%
$18.46200 day average+25.0%
$18.3250 day average+24.0%
$18.30100 day average+23.9%
$17.6020 day average+19.2%
$16.69Swing high (Jul 27)+13.0%
$15.07Pivot R1+2.0%
$14.82Pivot+0.3%
$14.77Last close
$14.75Swing low (Aug 3)−0.1%
$14.5852 week low−1.3%
$14.52Pivot S1−1.7%
Indicators
RSI (14)
31.20
Weak, oversold below 30
Neutral
MACD
-0.78
Below its signal line
Bearish
Stochastic
4.8
Near the bottom of its range
Oversold
ADX (14)
18.8
No clear trend
Williams %R
-96.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-179.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.3%
Change over 10 sessions
Bearish
ATR (14)
$0.91
Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 16.5%/day
Key levels
$24.6852 week high+67.1%
$18.46200 day average+25.0%
$18.3250 day average+24.0%
$18.30100 day average+23.9%
$17.6020 day average+19.2%
$16.69Swing high (Jul 27)+13.0%
$15.07Pivot R1+2.0%
$14.82Pivot+0.3%
$14.77Last close
$14.75Swing low (Aug 3)−0.1%
$14.5852 week low−1.3%
$14.52Pivot S1−1.7%
Indicators
RSI (14)
39.23
Weak, oversold below 30
Neutral
MACD
-0.73
Below its signal line
Bearish
Stochastic
13.8
Near the bottom of its range
Oversold
ADX (14)
10.7
No clear trend
Williams %R
-97.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-143.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−27.8%
Change over 10 sessions
Bearish
ATR (14)
$2.43
Typical daily range, 16.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for SRPT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SRPT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow SRPT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SRPT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRPT is in one of them and how their past SRPT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Sarepta Therapeutics
Sarepta Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts. It develops and sells gene therapy and other medicines for genetic diseases. One of its products, ELEVIDYS, is a gene therapy given to patients through infusion centers. Its customers include patients, specialist physicians, healthcare providers and payers that cover the cost of treatment.